Nonstructural protein 5A · SINGLE PROTEIN · Hepatitis C virus
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Nonstructural protein 5A shows approved-linked disease relevance led by chronic hepatitis C virus infection. 5 more disease programs remain visible in the same review block. 10 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q5L478. Start with chronic hepatitis C virus infection, then reuse UniProt Q5L478 as the stable protein anchor across project notes and exports.
Start with chronic hepatitis C virus infection, then reuse UniProt Q5L478 as the stable protein anchor across project notes and exports.
Nonstructural protein 5A shows approved-linked disease relevance led by chronic hepatitis C virus infection. 5 more disease programs remain visible in the same review block. 10 linked drugs remain visible in the same block.
Start review with chronic hepatitis C virus infection because it currently carries approved-linked support. Linked drugs include DACLATASVIR DIHYDROCHLORIDE, ELBASVIR, LEDIPASVIR, ODALASVIR. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyNonstructural protein 5A
Review this target as Nonstructural protein 5A, mapped to UniProt Q5L478. Sequence length is 447 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Nonstructural protein 5A as ChEMBL target CHEMBL3307224, mapped to UniProt Q5L478. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Nonstructural protein 5A is the right protein anchor across sources, using UniProt Q5L478 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why chronic hepatitis C virus infection is currently framed as approved-linked support. It currently carries 10 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Nonstructural protein 5A |
| Target Type | SINGLE PROTEIN |
| Organism | Hepatitis C virus |
| UniProt | Q5L478 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Nonstructural protein 5A |
| UniProt Accession | Q5L478 |
| Component Type | Protein |
| Sequence Length | 447 aa |
Nonstructural protein 5A
Review this target as Nonstructural protein 5A, mapped to UniProt Q5L478. Sequence length is 447 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Nonstructural protein 5A shows approved-linked disease relevance led by chronic hepatitis C virus infection. 5 more disease programs remain visible in the same review block.
Start review with chronic hepatitis C virus infection because it currently carries approved-linked support. Linked drugs include DACLATASVIR DIHYDROCHLORIDE, ELBASVIR, LEDIPASVIR, ODALASVIR. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL3360472 | 11.0 | EC50 | 0.01 | Preclinical |
| CHEMBL3545062 | 11.0 | EC50 | 0.01 | Approved |
| CHEMBL3763799 | 11.0 | EC50 | 0.01 | Preclinical |
| CHEMBL3765311 | 11.0 | EC50 | 0.01 | Preclinical |
| CHEMBL4214282 | 11.0 | EC50 | 0.01 | Preclinical |
| CHEMBL4440405 | 11.0 | EC50 | 0.01 | Preclinical |
| CHEMBL4443067 | 11.0 | EC50 | 0.01 | Preclinical |
| CHEMBL4543823 | 11.0 | EC50 | 0.01 | Preclinical |
| CHEMBL4575259 | 11.0 | EC50 | 0.01 | Preclinical |
| CHEMBL4579455 | 11.0 | EC50 | 0.01 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 186 | 407 | 9.3 |
| single protein format | 66 | 106 | 9.2 |
| assay format | 16 | 70 | 9.4 |